Skip to content
10-Q

Quarterly Report

INOVIO PHARMACEUTICALS, INC. INO

0001055726-26-000018

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 12, 2026 82.27M sh
Shares Diluted Q1 2026 · Mar 31, 2026 69.1M sh
Shares Diluted Q1 2026 · Mar 31, 2025 38.61M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $59.37K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$21.59M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$26.87M
Short Term Investments Q1 2026 · Mar 31, 2026 $11.41M
Short Term Investments Q1 2026 · Dec 31, 2025 $14.24M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $26.27M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $44.27M
Stockholders Equity Q1 2026 · Mar 31, 2026 $6.07M
Stockholders Equity Q1 2026 · Dec 31, 2025 $24.1M
Stockholders Equity Q1 2026 · Mar 31, 2025 $51.25M
Stockholders Equity Q1 2026 · Dec 31, 2024 $68.5M
Current Liabilities Q1 2026 · Mar 31, 2026 $37.92M
Current Liabilities Q1 2026 · Dec 31, 2025 $43.67M
Total Liabilities Q1 2026 · Mar 31, 2026 $43.71M
Total Liabilities Q1 2026 · Dec 31, 2025 $50.21M
Current Assets Q1 2026 · Mar 31, 2026 $39.44M
Current Assets Q1 2026 · Dec 31, 2025 $61.12M
Total Assets Q1 2026 · Mar 31, 2026 $49.78M
Total Assets Q1 2026 · Dec 31, 2025 $74.31M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.28
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.51
Eps Basic Q1 2026 · Mar 31, 2026 −$0.28
Eps Basic Q1 2026 · Mar 31, 2025 −$0.51
Sga Expense Q1 2026 · Mar 31, 2026 $7.88M
Sga Expense Q1 2026 · Mar 31, 2025 $9.02M
Rd Expense Q1 2026 · Mar 31, 2026 $14.07M
Rd Expense Q1 2026 · Mar 31, 2025 $16.09M
Net Income Q1 2026 · Mar 31, 2026 −$19.68M
Net Income Q1 2026 · Mar 31, 2025 −$19.69M
Operating Income Q1 2026 · Mar 31, 2026 −$21.95M
Operating Income Q1 2026 · Mar 31, 2025 −$25.05M
Revenue Q1 2026 · Mar 31, 2026 $0
Revenue Q1 2026 · Mar 31, 2025 $65.34K